Latest Breaking News On - Enriqueta filip - Page 1 : comparemela.com

Second-line atezolizumab plus cabozantinib did not generate a clinical benefit over standard-of-care docetaxel in patients with metastatic non–small cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy.

Comunidad autonoma de catalunaEnriqueta filipDepartment of oncology vallHebron university hospitalEuropean lung cancer congressLung cancerStrategy afterLung cancer congressPembrolizumab versus standardSitravatinib with nivolumabPatients with nonsquamousAfter checkpoint inhibitor therapyNon small cell lung cancer